REPLY
28.4.2022 14:02:13 CEST | Business Wire | Press release
Today Reply inaugurates Area42 , the new applied research centre focused on developing the most innovative technologies. The Area42 “corner Labs” are driven by cutting-edge work in the areas of Autonomous Warehouse, Last Mile Delivery, Robotics, Connected Products, Blockchain and the Metaverse . Reply’s experts are working on these technologies on a daily basis, transforming ideas into innovative prototypes, exploiting their full potential and applying them to real use industrial cases.
The Area42 Laboratories are the distinctive component of Reply’s new Turin headquarters, which covers an area of over 20,000 square metres. Each workspace has been completely renovated and optimised in line with the Group’s new working models, which focus on a more open and collaborative approach. Reply will host its customers in the new spaces, collaborating with them to experiment, incubate new concepts, and test the latest technologies in a way that enables digital products and services to be adapted to their specific innovation context.
The 6 Area42 Laboratories focus on the key themes representing the most advanced frontiers of innovation for the industrial world:
- Autonomous Warehouse, the Area42 laboratory where solutions are studied and developed for the autonomous management of warehouse activities, thanks to the use of autonomous drones and vehicles capable of interfacing with innovative warehouse management platforms such as LEA Reply;
- Last mile delivery , the Area42 laboratory focused on the mobility of self-driving vehicles and robots within pre-defined spaces (e.g., campuses, hospitals, factories, etc.) that are capable of interacting with the surrounding environment;
- Robotics , the Area42 laboratory that combines Artificial Intelligence technologies with robotics to study the agility of autonomous robots and use scenarios focused on the interaction between the latter and large environments requiring repetitive maintenance and control activities;
- Connected Products, the Area42 space focused on the design and development of connected products and services, from the prototyping of devices to the creation of front-end applications, also thanks to the support of IoT accelerators;
- Blockchain , in the context of an ever-greater evolution of the concepts of smart cities and shared mobility, this Area42 laboratory experiments with the application of blockchain technologies for enabling real scenarios based on the Digital Identity of Vehicles;
- Metaverse, the Area42 laboratory focused on the application and integration of Mixed Reality solutions to create immersive applications in virtual environments, where users can enter and move around and where virtual and physical objects co-exist.
“The Area42 laboratories represent a unicum in the modern technological panorama,” affirmed Filippo Rizzante, Reply CTO. “Here, we give life to new and innovative concepts and apply the latest technologies to provide solutions capable of creating value for business and for society as a whole. We experiment with and implement innovative ideas that have a strategic impact and generate a competitive advantage for our customers. Currently, our focus is on six highly topical issues, but technological evolution will always continue to drive us further, in line with what has always been our approach at Reply: to prepare for and make the future a tangible reality”.
Area42 joins Reply’s existing laboratories in Europe: the Test Automation Centre , focused on the automated monitoring and testing of the quality of business-critical products and services; the IoT Validation Lab , where interconnected solutions are validated and also integrated with Reply’s new Turin headquarters, creating the most advanced hub of laboratories for the industry sector; Area 360, the centre for augmented and virtual reality based in Milan which was created to support businesses; the Immersive Experience Lab in Munich, which experiments with next-generation immersive experiences; the Cyber Security Lab , in Cologne, focused on the study and testing of cyber threats; and finally, Reply’s new labs opening soon in London which will be dedicated to robotics, edge computing and sensory technologies.
“The creation of Area42 is part of a broader project of excellence in terms of property redevelopment that we have initiated here in Turin”, continues Tatiana Rizzante. “While carefully respecting the constraints imposed by the Superintendency of Architectural Heritage in relation to what is certainly considered a symbol of modern architecture, we wanted to create harmonious and stimulating spaces to work, exchange ideas and carry out research. The interconnection of spaces created to accommodate different functions – from individual to team work, from the sharing of projects to leisure time, from lounges to the most advanced laboratories – creates a fluid and open space. Our team of experts, but also our customers and partners, can thus take advantage of a truly immersive experience and experiment with technological innovation”.
The Lingotto building that hosts Area42, located in Via Nizza no. 250 in Turin and recently acquired by the Group, has been the subject of a major renovation project which, together with works currently under way at the former Caserma de Sonnaz, make it possible to revive and reinterpret – with a contemporary touch – two iconic buildings for the city of Turin.
The projects are driven by the concepts of innovation, collaboration and well-being, placing the focus on the two main protagonists: people and research.
The completely renovated Lingotto building offers open spaces and new paths, created to facilitate business relationships and enlivened by the most current languages and codes. Reply’s people find themselves immersed in a large, multi-functional space with areas off limits to mobile phones and meetings to facilitate concentration. Common areas are dedicated not only to brainstorming, but also to sports, catering and leisure, for a more effective sharing of ideas and socialisation in the workplace: an active and ever-evolving ecosystem.
Reply
Reply [MTA, STAR: REY, ISIN: IT0005282865] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005169/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
